In a new research released in The EMBO Journal.
Our discovery that anchored enzymes donate to the regulation of cellular occasions that underlie diabetes can help us to move more rapidly toward new therapies to control this progressively prevalent metabolic disease, commented John Scott, Edwin G. Krebs-Hilma Speights Professor of Pharmacology at the University of Washington College of Medicine, Seattle and an investigator of the Howard Hughes Medical Institute. The observation that AKAP 150 functions by coordinating phosphatase activity in the cell reveals a fresh function for these anchoring proteins in the control of glucose rate of metabolism and related metabolic disorders.Achillion’s past due breaking poster will become displayed in the Late Breaking Poster Session on Monday, 1 at 8:00 a November.m. Through the finish of the day’s program. The balance of the business’s posters will be displayed in the HCV Therapy: Preclinical and Early Clinical Advancement Poster Program on Tuesday, 2 at 7:00 a November.m. Through the end of the day’s program.’ SOURCE Achillion Pharmaceuticals, Inc.
Accuray receives shareholders approval to acquire TomoTherapy Accuray Integrated , a global leader in neuro-scientific radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Integrated by Accuray.